The Chemotherapy Market is segmented into various drug classes based on their mechanism of action, including Alkylating Agents, Antimetabolites, Mitotic Inhibitors, Topoisomerase Inhibitors, and Antitumor Antibiotics.

Leading and Fastest-Growing Segments (MRFR Analysis):

• Largest Segment (Revenue): Mitotic Inhibitors continue to dominate the market.

• Fastest-Growing Segment: Antimetabolites are witnessing rapid growth due to their effectiveness in various cancer types.

Alternative Analysis (Market Share):

• Alkylating Agents: This class, which includes drugs like cyclophosphamide and cisplatin, led the market with a $38.78\%$ share in 2024. They hold the largest share due to their wide application in several cancer types. Alkylating agents are estimated to contribute the highest market share of $54.7\%$ in 2025 in some reports.

• Antimetabolites: This segment is set to post a CAGR of $10.23\%$ through 2030, driven by the acceptance of biomarker-guided dosing.

Drug classes function by various mechanisms: Alkylating agents inhibit DNA replication, while Mitotic Inhibitors like Vincristine bind to tubulin, inhibiting microtubule formation and arresting cells in metaphase.

For a detailed analysis of the market share, growth drivers, and classification of Alkylating Agents, Antimetabolites, and Mitotic Inhibitors, consult the Chemotherapy Market Research Report.